<DOC>
	<DOC>NCT00002106</DOC>
	<brief_summary>To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.</brief_summary>
	<brief_title>A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3</brief_title>
	<detailed_description>Patients are randomized to receive either ranitidine or matching placebo bid for 16 weeks, with follow-up every 4 weeks through week 20.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<criteria>Inclusion Criteria Patients must have: Asymptomatic HIV1 infection. CD4 count of 400700 cells/mm3. Exclusion Criteria Coexisting Condition: Patients with the following symptoms or conditions are excluded: Significant illness. Acute illness at randomization. Hemodialysis. Prior Medication: Excluded: Antiretroviral use within 60 days prior to study entry.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1994</verification_date>
	<keyword>Ranitidine</keyword>
</DOC>